-
BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC
•
BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest results from the Phase II KeyPelms-004 study at the 39th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting. The study evaluated the efficacy and safety of plinabulin combined with pembrolizumab plus docetaxel in patients with…
-
Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is currently entangled in legal challenges involving two partner companies. The firm has initiated a lawsuit against US-based biotech BeyondSpring Inc. (NASDAQ: BYSI) over a failed partnership deal, while also facing potential disbandment of its subsidiary, Reistone Biopharma (Hong Kong) Ltd, amid…
-
NMPA Denies Market Approval for Hengrui’s Plinabulin in Chemotherapy-Induced Neutropenia
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the National Medical Products Administration (NMPA) has declined to issue a market approval for plinabulin, a potential first-in-class GEF-H1-targeted small-molecule drug in-licensed from US-based BeyondSpring Inc. (NASDAQ: BYSI). Hengrui was seeking approval for the drug’s use…
